Genome engineering is a process of insertion, deletion, modification or replacement of DNA bases in an organism. Genome engineering has exhibited potential benefits in gene therapy. For instance, various genetic disorders such as Hemophilia, Myotonic dystrophy, Alzheimer’s disease, Sickle cell anemia, Gaucher disease, Cystic fibrosis (involves correction of a single gene) or asthma, autoimmune diseases, cancer, diabetes, and heart disease (involves correction of multiple genes) can be treated using genomic engineering.
Increasing preference for personalized medicines and research and development is expected to propel growth of the genomic engineering market
Personalized medicine (pharmacogenomics and precision medicine) involves extensive use of genomic engineering for offering drugs specific to the patient’s condition. Companies and patients are opting for personalized medicine, for effective and precise treatment. This is especially applicable to treat chronic diseases such as cancer in which, precision medicine is of high interest to patients and prescribers. This factor is expected to drive growth of the genome engineering market. Pharmaceutical firms are increasingly focusing on genomic engineering for their research and development such as in target identification and validation, and clinical trials. As per the estimation of Pharmaceutical Research and Manufacturers of America (PhRMA), on an average the pharmaceutical industry invests US$ 0.8 to US$ 1.7 billion on research and development to bring one product to the market. Moreover, genome engineering aids in faster development of precision drugs. For instance, Crizotinib, which is an anti-cancer drug to treat lymphoma, was introduced in the market within seven years of research against the normal span of 14 years with the help of genome engineering. Furthermore, lowering cost to sequence the genome to as low as US$ 1,000 as against close to US$ 2 billion for human genome project is also expected to boost growth of the genome engineering market.
Genome Engineering Market Taxonomy
On the basis of technology, the global genome engineering market is segmented into:
On the basis of application, the global genome engineering market is segmented into:
On the basis of end user, the global genome engineering market is segmented into:
On the basis of region, the global genome engineering market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be dominant position in the genomic engineering market. This is owing to increasing research spending and collaboration with genomics firms by pharmaceutical and biotechnological companies in the region In April 2016, AstraZeneca launched project to sequence genome of over 2 million people by collaborating with biotech firm Human Longetivity, Inc., and other academic institutions. In March 2015, Genomics England announced to partner with 10 pharmaceutical and biotechnological companies to develop new diagnostics techniques and treatments for patient with cancers and rare disease, using the genomic sequences gathered through the 100,000 genomes project of Genomics England.
Key players in the market are focusing on acquisition and collaboration strategies for enhancing their market share and expanding their product portfolios. For instance, in January 2018, Sangamo Therapeutics entered into collaboration with Pfizer Inc. for development of zinc finger protease gene therapy to treat amyotrophic lateral sclerosis. Moreover, in December 2017, Horizon Discovery Group plc. Entered into agreement with Roche Diagnostics for development of immunohistochemistry assay. Merck KGaA in 2015 acquired Sigma-Aldrich at US$ 17 billion, now known as Millipore-Aldrich, in order to enhance its product offerings. In April 2017, the FDA re-approved 23andme to provide gene testing services, which would aid in testing the susceptibility of people for particular diseases. 23andme offers first direct-to-consumer gene testing tool kit.
Key players operating in the global genomic engineering market are Genscript Biotech Corporation, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Sangamo Therapeutics, Inc., Lonza Group, New England Biolabs, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Transposagen Biopharmaceuticals, Inc. Editas Medicine, CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Precision Biosciences, Inc., and Caribou Biosciences, Inc.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.